ReviewAlzheimer's research & therapy2015
Principles and management of neuropsychiatric symptoms in Alzheimer's dementia.
Review in Alzheimer's research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [Therapy strategies for repetitive vocalizations in dementia : A systematic review].Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2025Pooled it
- Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns.Molecular neurodegeneration · 2021Pooled it
- Neuropsychiatric Symptoms in Elderly With Dementia During COVID-19 Pandemic: Definition, Treatment, and Future Directions.Frontiers in psychiatry · 2020Pooled it
- Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.Nature medicine · 2025Trial
- Comparison of the efficacy of gesture-verbal treatment and doll therapy for managing neuropsychiatric symptoms in older patients with dementia.International journal of geriatric psychiatry · 2019Trial
- Ursolic acid reduces Aβ-driven aggression via Gab1-mediated autophagy and dorsal hippocampal circuit modulation in Alzheimer's disease.Journal of advanced research · 2026Article
- Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026Review
- Identification of the central symptoms of neuropsychiatric symptoms among older adults with mild cognitive impairment: a network analysis.Frontiers in psychiatry · 2026Article
- Facial Emotion Recognition Deficits and Electroencephalogram Alterations in Mild Behavioral Impairment.Neuro-degenerative diseases · 2026Article
- Neuropsychiatric symptoms in Alzheimer's disease: Bridging mechanisms, management, and emerging innovations.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Neuropsychiatric symptom phenotypes for early detection of risk in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Dementia Subtypes Defined Through Neuropsychiatric Symptom-Associated Brain Connectivity Patterns.JAMA network open · 2024Article
- Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients.Alzheimer's research & therapy · 2024Article
- Developing an ontology of non-pharmacological treatment for emotional and mood disturbances in dementia.Scientific reports · 2024Article
- Network analysis of neuropsychiatric symptoms in Alzheimer's disease.Alzheimer's research & therapy · 2023Article
- Network Analysis of Neuropsychiatric Symptoms in Alzheimer's Disease.Research square · 2023Article
- Article
- The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2022Article
- Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer's Disease.Journal of personalized medicine · 2022Review
- Spatio-Temporal Dynamics of Entropy in EEGS during Music Stimulation of Alzheimer's Disease Patients with Different Degrees of Dementia.Entropy (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric symptoms of Alzheimer's disease (NPS-AD) are highly prevalent and lead to poor medical and functional outcomes. In spite of the burdensome nature of NPS-AD, we are continuing to refine the nosology and only beginning to understand the underlying pathophysiology. Cluster analyses have frequently identified three to five subsyndromes of NPS-AD: behavioral dysfunction (for example, agitation/aggressiveness), psychosis (for example, delusions and hallucinations), and mood disturbance (for example, depression or apathy). Recent neurobiological studies have used new neuroimaging techniques to elucidate behaviorally relevant circuits and networks associated with these subsyndromes. Several fronto-subcortical circuits, cortico-cortical networks, and neurotransmitter systems have been proposed as regions and mechanisms underlying NPS-AD. Common to most of these subsyndromes is the broad overlap of regions associated with the salience network (anterior cingulate and insula), mood regulation (amygdala), and motivated behavior (frontal cortex). Treatment strategies for dysregulated mood syndromes (depression and apathy) have primarily targeted serotonergic mechanisms with antidepressants or dopaminergic mechanisms with psychostimulants. Psychotic symptoms have largely been targeted with anti-psychotic medications despite controversial risk/benefit tradeoffs. Management of behavioral dyscontrol, including agitation and aggression in AD, has encompassed a wide range of psychoactive medications as well as non-pharmacological approaches. Developing rational therapeutic approaches for NPS-AD will require a firmer understanding of the underlying etiology in order to improve nosology as well as provide the empirical evidence necessary to overcome regulatory and funding challenges to further study these debilitating symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.